Quantcast

Latest AstraZeneca Stories

2014-10-30 08:36:43

SAN FRANCISCO, Oct. 30, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2014 on Thursday, November 6, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference call...

2014-10-29 16:30:07

MERIDEN, Conn., Oct. 29, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that the U.S. FDA has approved Flublok influenza vaccine for all adults aged 18 years and older, granting approval for use in people 50 and older under the accelerated approval of biological products regulations, 21 CFR 601.40-46. Flublok is the only licensed flu vaccine that is made using modern recombinant technology and the only flu vaccine that is 100% egg-free and highly purified. It also...

2014-10-29 12:27:14

Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 29, 2014 /PRNewswire/ -- Decision Resources Group finds that the entry of 13 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.2 billion in 2013 to $8.5 billion in 2023. The entry of four immune checkpoint inhibitors, namely the programmed death-1 (PD-1) inhibitors Opdivo...

2014-10-28 12:30:39

Team approach will smooth transition home for patients, reduce readmissions WASHINGTON, Oct. 28, 2014 /PRNewswire-USNewswire/ -- The American College of Cardiology today announced 35 selected hospitals that are pioneering a team approach to keep patients healthy and at home following admission for heart attack or heart failure. The hospitals from across the country are the first participants in the ACC Patient Navigator Program, which is the first program of its kind in cardiology and...

2014-10-28 08:34:41

COSTA MESA, Calif., Oct. 28, 2014 /PRNewswire-iReach/ -- WCCT Global, a full Service Contract Research Organization headquartered in Southern California announced their involvement in a sentinel clinical trial designed to evaluate safety and immunogenicity signals from a novel oral vaccine for influenza, as opposed to injectable or intranasal vaccines. The study was first presented to the scientific community on October 14, 2014 at the World Vaccine Congress in Brussels, Belgium by...

2014-10-27 12:30:11

DUBLIN, Oct. 27, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global H1N1 Vaccines Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 H1N1 influenza (zoonotic) is an infectious disease in humans caused by a variant of the swine H1N1 virus, known as H1N1v virus. The H1N1v virus is a contagious virus which infects nose, throat, and lungs. H1N1 virus is an RNA virus belonging to the Orthomyxoviridae family. Influenza A...

2014-10-27 08:30:24

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, October 27, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Duke Energy Corporation (NYSE: DUK), Exelon Corporation (NYSE: EXC), Marriott International, Inc. (NASDAQ: MAR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and AstraZeneca PLC (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary...

2014-10-25 23:00:42

He will lead all research and development for the firm’s algae proteins used in human pharmaceuticals and specialty animal feed products. San Diego, CA (PRWEB) October 25, 2014 Triton Algae Innovations, a pioneer in synthetic biology, today announced Dr. Xun Wang has joined the firm as President and Director of all Research & Development. Triton has developed a patented synthetic biology platform for the production of high value algae-based proteins. According to Dr. Wang, the...

2014-10-23 12:29:39

FREMONT, Calif., Oct. 23, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Ardelyx, together with its development partner, AstraZeneca (NYSE:AZN, LON:AZN), will present tenapanor-related preclinical and clinical results during Kidney Week 2014, the annual meeting of the American Society of Nephrology (ASN). Abstracts of the presentations were published today on...

2014-10-23 08:34:00

INDIANAPOLIS, Oct. 23, 2014 /PRNewswire/ -- -- Third-quarter 2014 revenue declined 16 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista, partially offset by volume growth in most other products. -- Reported operating expenses declined 4 percent as ongoing cost containment initiatives were partially offset by expense associated with the U.S. Branded Prescription Drug Fee and costs related with the termination of...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related